Pharmaceutical Control of the
Human Microbiome


Ward Peterson, PhD
Co-founder, President and CEO

Dr. Peterson has 16 years experience in pharma R&D—drug discovery to Phase 3 studies involving multiple targets and therapeutic areas. His previous employment was with Regeneron Pharmaceuticals and Inspire Pharmaceuticals (Research Scientist to Senior VP).

Matthew Redinbo, PhD
Co-founder and Chief Scientific Officer
Dr. Redinbo is the inventor of Symberix's technology licensed from University of North Carolina, Chapel Hill. He has 25 years of experience in biochemistry, structural and chemical biology. Dr. Redinbo is the Kenan Distinguished Professor of Chemistry, Biochemistry, Microbiology and Genomics at UNC, Chapel Hill.
Anil K. Goyal, Ph.D., CLP
Chief Business Officer

Dr. Goyal brings 23+ years of experience at private and public biotechnology companies. He has led business development, operations, strategic planning, deal making, in/out-licensing, mergers and acquisitions for therapeutics and diagnostics companies across multiple disease areas, especially immuno-oncology.   From 2013-2016 he was Vice President of Business Development and member of management team at Heat Biologics, a NASDAQ listed (HTBX) immuno-oncology company. From 2010-2013 he was CEO and co-founder of Qualiber, Inc., a cancer nanomedicine company launched from UNC-Chapel Hill.  During 2009-2012 he led business development for Ascletis Pharmaceuticals (Hangzhou) Pvt. Ltd., and Optherion, Inc.  In 2008 Dr. Goyal led strategic plan that resulted in the acquisition of Serenex by Pfizer. Earlier in his career he had key business and scientific roles at Millennium Pharmaceuticals, Inc. (acq. by Takeda), Genome Therapeutics Corporation, and Merck & Co.

Dr. Goyal received his Ph.D. degree in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey.  He holds the Certified Licensing Professional (CLP™) credential from the Licensing Executives Society (USA and Canada), Inc. (LES).